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Abstract
Background. Effective treatment for patients at least 70 years with newly diagnosed glioblastoma remains chal-
lenging and alternatives to conventional cytotoxics are appealing. Autophagy inhibition has shown promising 
efficacy and safety in small studies of glioblastoma and other cancers.
Methods. We conducted a randomized phase II trial to compare radiotherapy with or without hydroxychloroquine 
(2:1 allocation). Patients aged at least 70 years with newly diagnosed high-grade glioma deemed suitable for short-
course radiotherapy with an ECOG performance status of 0–1 were included. Radiotherapy treatment consisted of 
30 Gy, delivered as 6 fractions given over 2 weeks (5 Gy per fraction). Hydroxychloroquine was given as 200 mg 
orally b.d. from 7 days prior to radiotherapy until disease progression. The primary endpoint was 1-year overall 
survival (OS). Secondary endpoints included progression-free survival (PFS), quality of life, and toxicity.
Results. Fifty-four patients with a median age of 75 were randomized between May 2013 and October 2016. The 
trial was stopped early in 2016. One-year OS was 20.3% (95% confidence interval [CI] 8.2–36.0) hydroxychloroquine 
group, and 41.2% (95% CI 18.6–62.6) radiotherapy alone, with a median survival of 7.9 and 11.5 months, respec-
tively. The corresponding 6-month PFS was 35.3% (95% CI 19.3–51.7) and 29.4% (95% CI 10.7–51.1). The outcome in 
the control arm was better than expected and the excess of deaths in the hydroxychloroquine group appeared un-
related to cancer. There were more grade 3–5 events in the hydroxychloroquine group (60.0%) versus radiotherapy 
alone (38.9%) without any clear common causation.
Conclusions. Hydroxychloroquine with short-course radiotherapy did not improve survival compared to radio-
therapy alone in elderly patients with glioblastoma.
Key Points
 • Hydroxychloroquine plus short-course radiotherapy (RT) did not improve survival 
compared to RT.
 • Standard doses of hydroxychloroquine may not enhance tumor regression with short-
course RT.
Hydroxychloroquine and short-course radiotherapy 
in elderly patients with newly diagnosed high-grade 
glioma: a randomized phase II trial
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The incidence of glioblastoma (GBM) appears to be 
increasing.1,2 In the UK, for example, the age-standardized 
rate has doubled to 5 per 100 000 person-years from 1995 
to 2015, including in elderly patients.1 These gliomas are 
especially difficult to treat, with a median survival of less 
than 12 months. Treatment options include debulking sur-
gery, temozolomide chemotherapy, radiotherapy, and 
combinations of these. However, conventional chemo-
radiotherapy delivered over 6 weeks is often poorly toler-
ated in patients aged older than 70 and can lead to worse 
outcomes than less intensive regimens.3–5 Short-course ra-
diotherapy with temozolomide in this patient group seems 
effective, though the benefit of adding temozolomide 
might be more pronounced for tumors exhibiting O6-
methylguanine-DNA-methyltransferase (MGMT) promoter 
methylation (about 40%).6–8 Although shorter treatment 
is tolerable for elderly patients and appealing because 
of fewer hospital visits, alternatives to conventional 
cytotoxics are needed.
Autophagy has been proposed as a relevant aspect of 
cancer biology for many years, although its role in either 
tumor promotion or prevention is debated.9 Increased 
autophagic flux allows tumor cell growth and survival, 
and conversely, autophagy can prevent tumor prolifera-
tion and inflammation.10,11 Either enhancing or inhibiting 
autophagy appears to have positive therapeutic effects, 
but most research is focused on inhibition.10 Preclinical 
and small early-phase clinical studies have investigated 
the autophagy inhibitors hydroxychloroquine or chloro-
quine for various cancers but with mixed findings.12–14 In 
GBM, interest has been in using these agents as a radia-
tion sensitizer and as adjuvant treatment, but their tumor-
suppressive properties are not fully understood, and 
inhibition alone might be insufficient to alter outcomes.15
Two small clinical trials and a retrospective review of 
patient records conducted before 2007 (all from the same 
institution) showed promising results in GBM. In a dou-
ble-blind, placebo-controlled trial, patients aged younger 
than 60 years received standard chemo-radiotherapy with 
or without 12 months of chloroquine. The median overall 
survival (OS) was 24  months for those given chloro-
quine but 11 months with placebo (hazard ratio [HR] 0.52, 
P = .14).16 A non-blinded randomized trial showed a marked 
increase in survival (median 33 months with chloroquine 
vs 11 months without, P < .001).17 Finally, among 41 GBM 
patients who chose to have chloroquine as part of their care 
the median OS was 25 months, compared to 11 months in 
82 patients who did not take chloroquine (P < .001).18
This prior evidence led us to develop a random-
ized study to examine the efficacy and tolerability of 
hydroxychloroquine combined with short-course ra-
diotherapy, specifically in elderly patients. We used 
hydroxychloroquine instead of chloroquine because it has 
a better toxicity profile.
Patients and Methods
We conducted an open-label randomized phase II trial.
Patients
Patients were eligible if they were aged at least 70 years 
with newly diagnosed histologically confirmed high-grade 
glioma, ECOG performance status 0/1, and life expect-
ancy of more than 2 months. They had to have adequate 
biochemistry, blood counts, and a Mini-Mental State 
Examination (MMSE) score at least 17 which is indicative 
of mild or no cognitive impairment. Prior macular degener-
ation, diabetic retinopathy, concurrent psoriasis, G6PD de-
ficiency, and any serious medical/psychological condition 
precluding study therapy, other malignancy, or previous 
therapy for glioma were exclusion criteria. All patients 
provided written informed consent and the trial was con-
ducted in accordance with the Declaration of Helsinki. The 
protocol was approved by the national research ethics 
committee.
Treatment
Patients were randomized (2:1) to receive short-course 
radiotherapy with or without hydroxychloroquine (ran-
domization was by minimization using sex and hospital 
as stratification factors). When the study was designed, 
temozolomide was not routinely used in this patient 
group hence MGMT status was not tested or included as a 
stratification factor.
Importance of the Study
This study represents the largest of 3 random-
ized trials in glioma and hydroxychloroquine 
(HCQ)/chloroquine. About 54 patients were 
randomized to receive radiotherapy with or 
without HCQ (2:1 allocation). The trial was 
stopped early in 2016 as the outcome in the 
control arm was better than expected and the 
excess of deaths in the HCQ group appeared 
unrelated to cancer. The results add useful in-
formation to the literature regarding the poten-
tial value of autophagy inhibition in glioma and 
other solid tumors. Our findings suggest that 
standard doses of hydroxychloroquine might 
not produce enhanced tumor regression with 
short-course radiotherapy. Investigators of sim-
ilar trials being conducted should also carefully 
monitor progression-free survival and overall 
survival. Results from ongoing and planned 
studies in glioma as well as other malignancies 
will further contribute to the growing evidence 
base for this type of therapy.
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Radiotherapy was planned to start within 28  days 
postsurgery (±3  days), delivered as 30 Gy in 6 fractions 
(5 Gy/day given on 3 nonconsecutive days over 2 weeks). 
Radiotherapy was planned using 3D-conformal compu-
terized tomography based on pre- and postoperative im-
aging, with scans taken at 2–3 mm intervals through the 
brain. Target volume definition was performed according 
to ICRU-50 and -62 guidance. The following organs at risk 
were delineated in all patients: optic chiasm, right and left 
optic nerves, pituitary gland, right and left ocular globes, 
right and left lenses, brain stem, and spinal cord.
Hydroxychloroquine was given orally as 200 mg tablets, 
twice daily, starting between 14 and 20 days postsurgery 
and at least 7  days before commencing radiotherapy. It 
was continued until progression or unacceptable toxicity 
including abnormal biochemistry or the development of 
visual symptoms. No dose modifications were allowed.
Concomitant use of enzyme-inducing antiseizure medi-
cations was not permitted. Oral steroid medications were 
used according to local practice.
Endpoints and Assessments
The primary endpoint was 1-year OS, measured from the 
date of randomization to the date of death from any cause. 
Patients who were alive were censored at the date last 
seen. Other endpoints included toxicity, progression-free 
survival (PFS), health-related quality of life (QoL), MMSE, 
and steroid dependence. PFS was defined as the time be-
tween randomization and death from any cause, local 
tumor progression or recurrence based on clinical evalu-
ation. Patients without a PFS event were censored at the 
date last seen.
Baseline assessments included postoperative magnetic 
resonance imaging (MRI) within 20 days of surgery, bio-
chemistry, and ophthalmology screening to exclude mac-
ular degeneration. Patients completed QoL questionnaires 
(EORTC-QLQ-C30 and the brain cancer module BN20) and 
the MMSE. Follow-up visits occurred at weeks 4, 8, and 
12 post-completion of radiotherapy and then bimonthly. 
Patients on hydroxychloroquine had an electrocardiogram 
(ECG) and ophthalmology review. The study protocol man-
dated MRI at the following time points: prior to surgery, 
following surgery, at 12 weeks following treatment, and 
thereafter as per standard clinical practice, scans were also 
undertaken if there was clinical suspicion of progression.
Statistical Considerations
We used a single-arm phase II A’Hern design, with a target 
1-year OS rate of 40% using hydroxychloroquine, assuming 
25% for radiotherapy alone (equivalent to a median sur-
vival of 9 vs 6 months). With one-sided 15% statistical sig-
nificance and 80% power, we required 38 patients to be 
given hydroxychloroquine, of which 13 need to be alive at 
1 year to justify further investigation. We also aimed to re-
cruit 19 control patients (to represent a 2:1 randomization 
allocation ratio), but the trial was not powered for a direct 
comparison between the groups.
HRs, along with 95% confidence intervals (CI) and 
two-sided P-values, were calculated using Cox proportional 
hazards regression. The survival curves with the esti-
mated 1  year and 6-month rates were calculated using 
the Kaplan–Meier method. Adverse events were graded 
using the National Cancer Institute Common Terminology 
Criteria for Adverse Events, v4. For each patient, the worst 
grade for each event type was used. Also, for each patient, 
the change in QoL score from baseline to 8 or 12 weeks 
posttreatment was calculated and compared between 
the treatment arms using the Wilcoxon test. All analyses 
were performed on an intention-to-treat basis using SAS 
(version 9.4).
The trial was closed early (October 20, 2016) upon recom-
mendation of the independent data monitoring committee 
(IDMC), because the data showed that the target efficacy 
for patients given hydroxychloroquine could not be met.
Results
Patient Characteristics
Fifty-four patients were randomized between May 2013 and 
September 2016 from 16 neuro-oncology centers across 
the UK National Cancer Research Network; one patient was 
found to be ineligible before starting hydroxychloroquine 
so was excluded from all analyses (Figure 1). Most patients 
were male (62%), the median age was 75 (range 70–83), 
and the majority of cases were diagnosed with GBM (89%). 
Baseline characteristics (Table  1) were well balanced ex-
cept for ECOG status in which a chance imbalance led to 
more patients who had performance status 0 being in the 
radiotherapy alone arm than the hydroxychloroquine arm: 
38.9 versus 11.4%.
Radiotherapy and Hydroxychloroquine 
Adherence
About 51 patients (96%) received 30 Gy radiotherapy, and 
only 2 patients did not start radiotherapy and 1 patient re-
ceived only 2 fractions (Figure 1). The median time from 
surgery to starting radiotherapy was 28 days; the timing 
was as per protocol for 42 patients, and it was started 
early (<25 days postsurgery) for 2 patients or started later 
(>31  days postsurgery) for 5 patients. Patients began 
hydroxychloroquine 10 days (median) prior to radiotherapy 
(range 5–21). The median duration of hydroxychloroquine 
was 94 days (range 11–340).
Additional Steroid Treatment
Steroid treatment (ie, dexamethasone) had been given at 
least once during the trial in 17 (94.4%) radiotherapy alone 
and 34 (97.1%) hydroxychloroquine patients.
Progression and Survival
When the IDMC decided to stop the trial early, 
the 1-year OS rate among patients who received 
hydroxychloroquine was 11% and with 4 more patients 
to recruit to the hydroxychloroquine group it was clear 
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that the target of 13 being alive at 1 year could not be 
achieved, and nor could the target OS rate of 40%. Also, 
the OS HR (hydroxychloroquine vs controls) was 2.18 
(95% CI 0.96–4.96, P = .06), which was too close to statis-
tical significance to ignore. Although there was no clear 
reason for the difference in OS it was not considered 
appropriate to continue to randomize patients to the 
experimental arm.
A final data chase was undertaken in April 2019 to identify 
deaths: 47 patients had died, 30 in the hydroxychloroquine 
arm and 17 in the radiotherapy alone arm. Disease pro-
gression was the cause of death in 34 (72%) patients 
(Supplementary Table 1).
The median OS was 7.9 versus 11.5  months in the 
hydroxychloroquine and radiotherapy alone arms, with 
corresponding 1-year OS of 20.3% (95% CI 8.2–36.0) 
and 41.2% (95% CI 18.6–62.6) (Figure  2). The excess of 
deaths in the hydroxychloroquine group was partly due 
to several single events apparently unrelated to cancer 
(Supplementary Table 1), such as lung infection, pulmo-
nary embolism, and myocardial ischemia. Six patients (5 
in short-course radiotherapy arm) had no cause of death 
recorded.
About 48 patients had a PFS event (progression or death 
from any cause); 31 in the hydroxychloroquine arm and 17 
in the radiotherapy alone arm. The 6-month PFS rate was 
  
SCRT only
(n = 18)
SCRT with HCQ
(n = 36)
Randomly
allocated
(N = 54)
Received trial RT
(n = 16)
Received trial RT
(n = 35)
Received HCQ
(n = 35)
Reasons:
Reasons:
Events:
Did not start RT (n = 2) Ineligible, excluded
Clinician decision (had 7 fractions, but 30Gy overall)
Patient progression (received 2 fractions)
On HCQ at final analysis (n = 1)
Did not complete treatment (n = 24)
Progression (n = 11)
Toxicity (n = 5)
(n = 1)
Trial stopped by the IDMC (n = 3)
Patient decision
Intracranial haemorrhage (grade 2)
(n = 3)Blurred vision (grade 1–2)
(n = 1)Rash maculopapular (grade 3)
(n = 2)
Clinician decision (n = 1)
Symptomatic deterioration (n = 1)
Did not receive protocol RT (n = 2)
(n = 1)
Included in analysis n = 35
Alive without progression (n = 0)
Alive with progression (n = 1)
Withdrawn from trial follow up (n = 4)
Died (n = 30)
Included in analysis n = 18
Alive without progression (n = 0)
Alive with progression (n = 0)
Withdrew consent from trial procedures (n = 1)
Died (n = 17)
Figure 1. Consort diagram.
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Table 1. Baseline Characteristics
Baseline Characteristics SCRT Only (n =18) SCRT + HCQ (n = 35)
Sex, n (%) Female 6 (33.3%) 14 (40.0%)
Male 12 (66.7%) 21 (60.0%)
Histology, n (%) Anaplastic astrocytoma 1 (5.6%) 2 (5.7%)
Glioblastoma 15 (83.3%) 32 (91.4%)
Gliosarcoma 1 (5.6%) 0
High-grade glioma 1 (5.6%) 1 (2.9%)
Surgery, n (%) Biopsy 10 (55.6%) 21 (60.0%)
Resection 8 (44.4%) 14 (40.0%)
ECOG, n (%) 0 (fully active) 7 (38.9%) 4 (11.4%)
1 (ambulatory but can work) 11 (61.1%) 31 (88.6%)
Age at entry (years) Median (range) 75.5 (70–82) 74.0 (70–83)
MMSE score Median (range) 28.5 (17–30) 27.0 (18–30)
SCRT, short-course radiotherapy; HCQ, hydroxychloroquine.
  
  
100
80
60
40
Su
rv
iva
l, 
%
20
SCRT
Experimental
18
35
17
30
14
28
12
21
11
14
9
9
7
6
4
3
3
2
3
1
2
1
2
1
0
0
0
0 2 4 6 8 10 12
Months since randomization
Kaplan—Meier plot for overall survivalA
B
14 16 18 20 22
SCRT
Experimental
24
100
80
60
40
Al
ive
 a
n
d 
pr
og
re
ss
io
n 
fre
e,
 
%
20
SCRT
Experimental
18
35
15
27
6
13
5
10
5
3
2
1
2
0
2
0
2
0
1
0
0
0
0
0 2 4 6 8 10 12
Months since randomization
Kaplan—Meier plot for progression free survival
14 16 18 20
SCRT
Experimental
Figure 2. Overall survival and progression-free survival. SCRT: short-course radiotherapy (control arm). Experimental: SCRT plus 
hydroxychloroquine.
  
 6 Brazil et al. HCQ and short-course RT for elderly glioma patients
35.3% (95% CI 19.3–51.7) with hydroxychloroquine and 
29.4 (95% CI 10.7–51.1) in those who received radiotherapy 
alone (Figure 2).
Although the trial was not designed for a direct com-
parison, the HR for OS for hydroxychloroquine compared 
to the control group was 1.55 (95% CI 0.84–2.89, P = .16). 
Because of an apparent imbalance in ECOG status at base-
line, we also calculated the HR adjusted for ECOG, which 
was 1.80 (95% CI 0.82–3.93, P = .14).
Adverse Events
Most patients experienced an adverse event during the 
trial, as expected for this elderly group with advanced 
cancer (Table 2). Two fatal adverse events occurred, both 
in the hydroxychloroquine group (lung infection and myo-
cardial infarction), but neither were considered by the cli-
nician to be related to the trial treatment. Supplementary 
Table 2 shows the adverse events of special interest in 
relation to hydroxychloroquine. Eye symptoms were 
seen in 2 patients (both low grade), and there was no ob-
vious imbalance between the trial groups nor any serious 
eye problems. There were more grade 3–5 events in the 
hydroxychloroquine group (60.0%) versus radiotherapy 
alone (38.9%): 21 versus 7 events (Supplementary Table 
3). However, the type of events was heterogeneous. The 
5 versus 0 lung infections were noted, but there is no 
known causal link between hydroxychloroquine and lung 
infection. Six patients stopped taking hydroxychloroquine 
early due to adverse events (Supplementary Table 4), with 
blurred vision as the reason for stopping for 3 patients.
QoL and MMSE
Thirty (56.6%) and 22 (41.5%) patients had QoL forms avail-
able at both baseline and 8 and 12 weeks, respectively. 
There were no significant differences in QoL between the 
treatment arms (Supplementary Table 5; Figures  3 and 
4). The median (range) last available MMSE score was 
26 (7–29) in the radiotherapy alone and 27 (10–30) in the 
hydroxychloroquine group (Kruskal Wallis P = .38). The me-
dian difference (range) in the MMSE score from baseline to 
the last score was 0 (−15; 0) in the radiotherapy alone and 
0 (−14; 4) in the hydroxychloroquine group (Kruskal Wallis 
P = .74).
Discussion
More than 20% of patients with high-grade glioma are 
aged at least 70 years when diagnosed. Short-course radi-
otherapy plus temozolomide is effective,8 but is associated 
with grade 3–4 hematological toxicity (27% lymphopenia, 
8% neutropenia, and 11% thrombocytopenia). Elderly pa-
tients not eligible for combined chemo-radiation could ben-
efit from either temozolomide alone or hypofractionated 
radiotherapy alone, with likely greater benefit from 
temozolomide in patients with MGMT promoter methyl-
ated tumors.19 At the time this study was designed, prior to 
reports of the relevance of temozolomide in these patients, 
MGMT testing was not carried out routinely for this patient 
group hence it was not used as a biomarker in this study. 
The strongest effect of MGMT status is in patients treated 
with temozolomide, which was not part of treatment in our 
study. in view of this, and the fact that the difference in HR 
between our groups was large, we do not think it likely that 
a subgroup effect explains the outcome data. It is note-
worthy that there remain very few randomized trials in this 
patient group, and that to date there has been no formal 
comparison of the standard chemo-radiotherapy used in 
younger patients against any alternative regime stratified 
by MGMT status.
Despite long-running interest in autophagy inhibi-
tion for treating cancer and promising data from other 
groups, our trial did not show improved outcomes for 
hydroxychloroquine when added to short-course radio-
therapy in elderly patients, and OS was lower than in the 
controls. Short-course radiotherapy alone was effective 
in our trial patients, exhibiting outcomes better than ex-
pected. Although there were only 18 patients in our con-
trol group, the median OS (11.5 months) was higher than in 
the equivalent arm of the trial by Perry et al.8 (7.6 months), 
although the median PFS is similar (3.6 in our study and 
3.9  months in the Perry et  al. trial). Indeed, our median 
OS was higher than the patients who received a combi-
nation of temozolomide and radiotherapy in that study 
(9.3 months).8 We were reassured that the median OS for 
  
Table 2. Adverse Events Summary
Adverse Events SCRT Only n = 18 SCRT + HCQ n = 35
n (%)
Any 15 (83.3) 34 (97.1)
Grade 3–5a 7 (38.9) 21 (60.0)
Grade 3–4 of special interest for hydroxychloroquinea 2 (11.1) 3 (8.6)
Grade 5 (deaths) 0 2 (5.7)b
Discontinued trial treatment due to adverse eventa 0 6 (17.1)
SCRT, short-course radiotherapy; HCQ, hydroxychloroquine.
aSee Supplementary Appendix Table 1; Supplementary Tables 2, 3 and 4 for details.
bLung infection and myocardial infarction.
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our patients who received hydroxychloroquine with ra-
diotherapy (7.9  months) was comparable to the radio-
therapy alone arm in the Perry et al. trial (7.6 months), in 
that adding hydroxychloroquine did not appear to disad-
vantage patients.19 Both trials include similar patients, al-
though there are differences in the radiotherapy regimen 
and ECOG status. Perry et  al. used 40 Gy in 15 fractions 
delivered over 3 weeks; we used 30 Gy over 6 fractions in 2 
weeks. The ECOG status was more favorable in our study, 
with 21% and 79% who had baseline performance status 0 
and 1 respectively, compared to 23%, 54%, and 23% with 
performance status 0, 1, and 2 in the Perry et al. trial. That 
trial also included only patients with GBM, whereas we in-
cluded patients with grade 3 astrocytoma.19
Because all patients received radiotherapy in our trial 
and adherence was high, the noticeable survival difference 
between the 2 groups could be due to an unexpectedly 
good outcome in this particular (and small) control group 
that was a chance finding, rather than a direct detrimental 
effect of hydroxychloroquine. The better performance 
status in patients who received radiotherapy only might 
also influence the difference. Alternatively, there might be 
some unexplained negative effect of combination therapy. 
However, the toxicity data do not support this, and the ex-
cess causes of deaths in the hydroxychloroquine group 
did indicate any obvious biologically plausible pattern. 
Nevertheless, the IDMC felt that they could not ignore the 
difference in survival, regardless of the reason, so stopped 
the trial early.
Metabolic reprogramming is a hallmark of many can-
cers including glioma and metabolic stress is known to 
activate the autophagy pathway, which is a pro-survival 
mechanism in this context. Several groups have published 
data suggesting that inhibition of autophagy can sensi-
tize tumor cells to chemotherapy and radiotherapy.20,21 
Hydroxychloroquine accumulates in the autophagosome 
and inhibits the late stages of autophagy that depend on 
autophagosome and lysosome function. Since it is an ex-
tremely well-characterized drug with a low toxicity profile, 
there are many ongoing studies investigating the addi-
tional benefit of hydroxychloroquine in a variety of solid 
and hematologic malignancies. Experimental studies 
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Figure 3. EORTC-QLQC30 quality-of-life functional scales. Scores are on a scale 0 (poor) to 100 (good) health. A positive difference indi-
cates that hydroxychloroquine (HCQ) was better than radiotherapy, and a negative difference indicates that radiotherapy alone was better. 
The median difference shown by the red bars.
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specifically of glioma cells support the potential for chlo-
roquine to have antitumor activity, on its own or with 
temozolomide22–25; one study showed that it enhances ra-
diation sensitivity.24
The 2 small previous randomized clinical trials of GBM 
which reported remarkable results using chloroquine with 
radiotherapy were small (18 and 30 patients, respectively) 
and based on younger patients.16,17 However, a later trial 
of newly diagnosed GBM evaluated hydroxychloroquine 
combined with radiotherapy and temozolomide: 16 pa-
tients in the phase I dose-escalation cohort and 76 in the 
subsequent phase II stage.26 They found that 600 mg per 
day was the maximum tolerated dose, with no material 
improvement in OS among the large phase II cohort. Their 
pharmacokinetic analyses and assessment of autophagy 
inhibition in peripheral blood lymphocytes led the authors 
to conclude that autophagy inhibition was not consist-
ently achieved at 600 mg.26 Phase I/II studies27,28 of mixed 
advanced solid tumors also suggest that higher doses 
(1200  mg/day) may be necessary to inhibit autophagy, 
though in these studies hydroxychloroquine was only com-
bined with either temozolomide or temsirolimus. Although 
no dose-limiting toxicities were observed, even at the high 
dose, evidence of antitumor activity mainly occurred in 
patients with melanoma.27,28 These data suggest that the 
dose we used in our trial (400 mg/day) might have been 
sub-therapeutic, but when we designed the trial we were 
mindful of the toxicity evidence at that time in the context 
of an elderly patient group. There is continued interest in 
the comparative activity between hydroxychloroquine and 
chloroquine as well as the use of other chloroquine like 
agents, including mefloquine, which may have improved 
blood-brain barrier penetration.23
Several other early-phase trials have combined 
hydroxychloroquine or chloroquine with various estab-
lished cancer therapies including vorinostat, erlotinib, 
sirolimus, gemcitabine, and bortezomib with mixed out-
comes. The appropriate dose of hydroxychloroquine/
chloroquine recommended in these studies has also 
been variable,29–34 partly because of heterogeneity in pa-
tient tolerability, which depends on the agent it is com-
bined with. Chloroquine has shown some efficacy in 
treating brain metastases when added to whole-brain 
radiotherapy. One trial reported a high local control rate 
of 88% in 16 patients,35 while in a double-blind placebo-
controlled trial (73 patients) the one-year PFS rate was 
84 versus 55% (chloroquine vs placebo, P = 0.008), with 
a nonstatistically significant improvement in OS (me-
dian 10.2 vs 7.4  months).36 Ongoing early-phase trials 
are assessing the effect of adding chloroquine to chemo-
radiotherapy in GBM multiforme (NCT023788532, 
NCT02432417), which may exploit the potential for sen-
sitizing to both radiation and temozolomide.37 In one of 
these (dose-escalation) trials, 13 newly diagnosed pa-
tients were given radiotherapy and temozolomide, and 
the maximum tolerated dose of chloroquine was deter-
mined to be 200 mg per day; 400 mg per day was asso-
ciated with toxicities.Serious adverse events included 
ECG QTc prolongation (n = 2), irreversible blurred vision 
(n = 1), and grade 3 nausea/vomiting (n = 3).38
Sensitivity to autophagy inhibition may be influenced 
by other tumor-specific factors including growth factor 
signaling, and recent preclinical data suggest that gliomas 
with either EGFRvIII or BRAFV600E mutations may be specif-
ically sensitive.39–41 These data suggest that patient selection 
for specific biomarkers may play an important role in re-
sponse rates and should be accounted for in future studies.
In conclusion, our trial, the largest of only 3 random-
ized trials in glioma and hydroxychloroquine/chloroquine 
adds useful information to the literature regarding the po-
tential value of autophagy inhibition in glioma and other 
solid tumors. Our findings suggest that standard doses of 
hydroxychloroquine might not produce enhanced tumor 
regression with short-course radiotherapy. Investigators 
of similar trials being conducted should also carefully 
monitor PFS and OS. Results from ongoing and planned 
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Figure 4. EORTC-QLQC30 quality-of-life symptom scales. Scores are on a scale 0 (good) to 100 (poor) health. A negative difference indicates that 
HCQ was better than radiotherapy, and a positive difference indicates that radiotherapy alone was better. The median difference shown by the 
red bars.
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studies in glioma as well as other malignancies will further 
contribute to the growing evidence base for this type of 
therapy.
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